XML Template (2009) [5.9.2009–3:06pm] [1–12]
{TANDF_FPP}CMO/CMO_A_370883(NEW).3d (CMO) [First Proof]
Current Medical Research and Opinion
C213
Volume 25, Number 3 2008
20
0.44)
20
63.0 53.0
(
p
¼
19 19
survival
0.341)
61.0 43.0 14.2 15.0
—
—
17.2 17.8 15.2
(months) (
p
¼
Overall
20
(weeks)
0.08)
20
0.095)
0.0001)
18.9
¼
14.7 17.0 16.1 21.6 28 31.2 25.2
(
p
(
p
¼
(
p
5
12
days.
Progression-free survival
28
every
19 19
(%)
0.39)
20.5 13.2 17.0
¼ —
— q28d:
27.8 36.1 31.6
ORR
(
p
19.7
days;
21
every
q21d:
(
platinum-
n
226
(107/119)
474
(220/254)
349 502
(294/208)
daily;
qd:
Patients,
sensitive/resistant)
weeks;
4
2
;
8;
i.v.), q4w
oral
every
h 1—5 (third-
q3w
infusion
(3
infusion
mg/m
day
i.v.), 5
and
q3w
and
on
2
on
i.v.
2
i.v. h days
1–5
or
2
q4w:
2 2
(1
2
2
2
/day;
2
/day
2
/day
mg/m
mg/m
2
days
mg/m
weeks;
Dose
mg/m mg/m mg/m
2
mg/m
mg/m
mg/day;
mg/m
3
cancer.
q3w
175
q3w 50
mg/m
800
1.5 1.5
mg/m
1.5
7 600
50
mg/m 1.25 1.0 0.5
1–5, 1–5,
q3w
q3w
and
every
ovarian
1.25
1, 1
days Paclitaxel: q21d days PLDH: or line); day etoposide gemcitabine day q3w
q3w:
Topotecan: Topotecan: Topotecan: Treosulphan: Topotecan Topotecan Topotecan
relapsed
doxorubicin;
with
PLDH
paclitaxel
patients
vs.
treosulphan liposomal
in
vs.
vs.
Treatment
pegylated
Topotecan
topotecan
Topotecan
Topotecan
PLDH:
i.v.
of
rate;
43
trials
III
.,
al
2008
et
., .,
al 21
., al
response
Phase
19,20 et
al
22
et
2.
Bokkel
2001
et
2003 overall
Huinink 1997
Study ten Gordon Meier Sehouli ORR:
Table
4
Topotecan for relapsed ovarian cancer Sehouli & Oskay-O
¨
zcelik www.cmrojournal.com
!
2009 Informa UK Ltd
Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34